PDGFRB and systemic sclerosis: Finally, the rather disappointing results from the use of the non-selective c-Abl, PDGFR, c-kit inhibitor imatinib in SSc clinical trials ([54]–[56] and reviewed in [57]) may in part be explained by the involvement of EGFR, as we observed in our study.